Pia Herbolsheimer

1.9k total citations
32 papers, 777 citations indexed

About

Pia Herbolsheimer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Pia Herbolsheimer has authored 32 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Genetics. Recurrent topics in Pia Herbolsheimer's work include HER2/EGFR in Cancer Research (12 papers), Cancer Treatment and Pharmacology (12 papers) and PARP inhibition in cancer therapy (11 papers). Pia Herbolsheimer is often cited by papers focused on HER2/EGFR in Cancer Research (12 papers), Cancer Treatment and Pharmacology (12 papers) and PARP inhibition in cancer therapy (11 papers). Pia Herbolsheimer collaborates with scholars based in United States, South Korea and United Kingdom. Pia Herbolsheimer's co-authors include Christopher Gresty, Helen K. Angell, Susan M. Domchek, Mark C. Lanasa, Y.H. Park, Maja J.A. de Jonge, Sook Hee Hong, Bella Kaufman, Karen L. Smith and Kassondra Meyer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Pia Herbolsheimer

30 papers receiving 768 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pia Herbolsheimer United States	17	664	200	139	122	111	32	777
Graziela Zibetti Dal Molin Brazil	10	436 0.7×	210 1.1×	87 0.6×	17 0.1×	74 0.7×	26	579
Pierre‐Marie Morice France	7	243 0.4×	97 0.5×	39 0.3×	81 0.7×	33 0.3×	21	382
Anna Maria Mosconi Italy	13	364 0.5×	140 0.7×	90 0.6×	27 0.2×	20 0.2×	39	558
Christos Mikropoulos United Kingdom	11	286 0.4×	175 0.9×	179 1.3×	5 0.0×	33 0.3×	21	483
Laura Mansi France	12	228 0.3×	85 0.4×	94 0.7×	15 0.1×	57 0.5×	30	373
Αngeliki Andrikopoulou Greece	13	220 0.3×	158 0.8×	89 0.6×	14 0.1×	30 0.3×	41	438
Amer Sami Canada	12	344 0.5×	184 0.9×	85 0.6×	22 0.2×	132 1.2×	23	551
Cyril Abdeddaim France	10	302 0.5×	77 0.4×	92 0.7×	8 0.1×	66 0.6×	30	519
Choichiro Ozu Japan	12	269 0.4×	158 0.8×	146 1.1×	8 0.1×	52 0.5×	22	579
Ana T. Nunes United States	11	275 0.4×	120 0.6×	70 0.5×	6 0.0×	81 0.7×	19	455

Countries citing papers authored by Pia Herbolsheimer

Since Specialization

Citations

This map shows the geographic impact of Pia Herbolsheimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pia Herbolsheimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pia Herbolsheimer more than expected).

Fields of papers citing papers by Pia Herbolsheimer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pia Herbolsheimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pia Herbolsheimer. The network helps show where Pia Herbolsheimer may publish in the future.

Co-authorship network of co-authors of Pia Herbolsheimer

This figure shows the co-authorship network connecting the top 25 collaborators of Pia Herbolsheimer. A scholar is included among the top collaborators of Pia Herbolsheimer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pia Herbolsheimer. Pia Herbolsheimer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolaney, Sara M., Zefei Jiang, Qingyuan Zhang, et al.. (2025). Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine. 394(6). 551–562. 2 indexed citations

Saura, Cristina, Javier Cortés, Shanu Modi, et al.. (2025). Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03. Annals of Oncology. 37(3). 353–363.

Saura, Cristina, Shanu Modi, Sung‐Bae Kim, et al.. (2024). Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) from DESTINY-Breast-01, -02, and -03.. Journal of Clinical Oncology. 42(16_suppl). 1023–1023.

Krebs, Matthew, Jean‐Pierre Delord, T.R. Jeffry Evans, et al.. (2023). Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. Lung Cancer. 180. 107216–107216. 27 indexed citations

Tolaney, Sara M., Romualdo Barroso‐Sousa, Zefei Jiang, et al.. (2022). Abstract OT1-14-02: Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Cancer Research. 82(4_Supplement). OT1–14. 3 indexed citations

Khoury, Katia, Filipa Lynce, Ana Barac, et al.. (2021). Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment. 185(3). 863–868. 20 indexed citations

Tolaney, Sara M., Romualdo Barroso‐Sousa, Y.H. Park, et al.. (2021). 328TiP Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09. Annals of Oncology. 32. S507–S508. 16 indexed citations

André, Fabrice, Erika Hamilton, Sherene Loi, et al.. (2021). Abstract OT-03-04: Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07). Cancer Research. 81(4_Supplement). OT–3. 1 indexed citations

Schmid, Peter, Seock‐Ah Im, Anne Armstrong, et al.. (2021). BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).. Journal of Clinical Oncology. 39(15_suppl). 1023–1023. 79 indexed citations

10.

Domchek, S. M., Sophie Postel‐Vinay, S-A. Im, et al.. (2019). Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Cancer Research. 79(4_Supplement). PD5–4. 16 indexed citations

11.

Lynce, Filipa, Ana Barac, Xue Geng, et al.. (2019). Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Research and Treatment. 175(3). 595–603. 102 indexed citations

12.

Domchek, S. M., Sophie Postel‐Vinay, Y-J. Bang, et al.. (2018). Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC). Cancer Research. 78(4_Supplement). PD6–11. 41 indexed citations

13.

Tutt, Andrew, Bella Kaufman, Judy E. Garber, et al.. (2017). OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm). Annals of Oncology. 28. v67–v67. 16 indexed citations

14.

Krebs, Matthew, Maja J.A. de Jonge, Fabrice Barlési, et al.. (2017). P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC. Journal of Thoracic Oncology. 12(11). S2044–S2045. 27 indexed citations

15.

Tefera, Eshetu, Pia Herbolsheimer, Raquel Nunes, et al.. (2017). Video intervention increases participation of black breast cancer patients in therapeutic trials. npj Breast Cancer. 3(1). 36–36. 20 indexed citations

16.

Barac, Ana, Filipa Lynce, Karen L. Smith, et al.. (2016). Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. Breast Cancer Research and Treatment. 155(2). 285–293. 16 indexed citations

17.

Nunes, Raquel, Mihriye Mete, Pia Herbolsheimer, et al.. (2016). Genomic profiling of breast cancer in African-American women using MammaPrint. Breast Cancer Research and Treatment. 159(3). 481–488. 12 indexed citations

18.

Purvey, Sneha, et al.. (2014). The effect of denosumab on kidney function in patients with metastatic breast cancer to bone previously treated with zoledronic acid.. Journal of Clinical Oncology. 32(15_suppl). e20701–e20701. 1 indexed citations

19.

Herbolsheimer, Pia, Rakesh Kapoor, Karen L. Smith, et al.. (2012). Phase I trial of dasatinib and ixabepilone in patients with solid tumors. Investigational New Drugs. 31(1). 92–98. 9 indexed citations

20.

Isaacs, Claudine, Pia Herbolsheimer, Minetta C. Liu, et al.. (2010). Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Research and Treatment. 125(1). 137–143. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact